Shares of Bristol-Myers Squibb (BMY +0.90%) have soared more than 27% since the start of this year, surpassing not only the S&P 500, but also its peers Eli Lilly (LLY +1.43%) and AstraZeneca (AZN +0.42%). What have been the main drivers of this growth, and how is Bristol-Myers valued today compared to other stocks in this competitive industry? In the following segment, taken from The Motley Fool's health care show Market Checkup, health care analysts David Williamson and Max Macaluso discuss an important valuation metric that all investors should pay attention to and why Bristol-Myers trades at a premium to many of its peers.
What's Behind Bristol-Myers Squibb's High Valuation?
By Max Macaluso and Dave Williamson – Aug 21, 2013 at 11:00AM
NYSE: BMY
Bristol Myers Squibb
Market Cap
$91B
Today's Change
(0.90%) $0.40
Current Price
$44.94
Price as of October 22, 2025 at 2:52 PM ET
Shares of Bristol-Myers Squibb have soared this year --- but what's been driving this growth?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo